Salah Uddin, MD
Nephrology · Tulsa, OKNPI 1861676736
Payments from drug & device makers
Across 47 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$283
- AstraZeneca$128
- Merck$121
- Calliditas Therapeutics US Inc.$77
- Veloxis Pharmaceuticals, Inc.$72
- Vifor Pharma, Inc.$70
- plus $226 from 7 others
What the payments were for
- Food & beverage$94497%
- Education$323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $283 |
| AstraZeneca | 6 | $128 |
| Merck | 7 | $121 |
| Calliditas Therapeutics US Inc. | 3 | $77 |
| Veloxis Pharmaceuticals, Inc. | 2 | $72 |
| Vifor Pharma, Inc. | 3 | $70 |
| Novo Nordisk | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Cormedix Inc. | 1 | $31 |
| Ardelyx, Inc. | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| Bayer | 1 | $18 |
How this compares
$976 in reported general payments places this provider in the 30th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lanthanum Carbonate | 11 | $8,837 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $6,193 |
| Cinacalcet Hcl | 32 | $1,885 |
| Potassium Chloride | 63 | $1,308 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $1,307 |
| Calcitriol | 63 | $1,074 |
| Nifedipine ErNifedipine | 36 | $595 |
| Fluconazole | 18 | $479 |
| Famotidine | 45 | $350 |
| Amlodipine Besylate | 41 | $295 |
| Atorvastatin Calcium | 31 | $228 |
| Tamsulosin Hcl | 14 | $159 |
| Hydralazine Hcl | 30 | $148 |
| Carvedilol | 43 | $137 |
| Pantoprazole Sodium | 12 | $109 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Tulsa
- Sunil AgrawalTulsa$40K
- Pranay KathuriaTulsa$21K
- Kevin FuTulsa$14K
- Diptesh GuptaTulsa$13K
- Janet RussellTulsa$12K
- Bobby MuthalalyTulsa$12K
- Narottam RegmiTulsa$12K
- Alpana PasrichaTulsa$9K
- Reza AzadiTulsa$9K
- Christine WilsonTulsa$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.